Addex Therapeutics Ltd - ADR Aktie News

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Participants Timothy Dyer - Co-Founder, CEO & Director Mikhail Kalinichev - Head of Translational Science Conference Call Participants Bob Pooler - ValuationLAB AG Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering t...

Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results o...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurode...

Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing...

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM).

Strong cash position of CHF2.8 million at end of Q1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for an exclusive license to intellectual proper...